Move to topTop
April 24, 2018

TOKYO, JAPAN - April 24, 2018 - Terumo Aortic announced the European limited market release of the RelayPro Thoracic Stent-Graft System at the 2018 Charing Cross conference. RelayPro is a low profile, next generation device designed to expand the treatment of thoracic endovascular aortic repair (TEVAR) to patients with smaller access vessels. Utilising the same stent design, material, and Dual Sheath Technology of the proven RelayPlus with a 3 to 4 Fr reduction in outer profile, RelayPro delivers the accuracy, control and confidence of the RelayPlus without compromising device integrity and durability. RelayPro offers physicians a wide range of diameters, lengths, tapers, and proximal configurations. Available in both Bare Stent and Non-Bare Stent (NBS) versions, RelayPro can be individualised to meet the specific anatomical needs of patients.

Mark Miles, Global Vice President of Marketing at Terumo Aortic, said: "By combining the proven stent design and material of RelayPlus with a lower outer profile, RelayPro enables percutaneous access to treat a larger patient population. This advancement not only expands patient applicability but will help improve access site complications and ultimately reduce the burden of rising global healthcare costs."

RelayPro is currently enrolling in multiple trials in US and Japan for treatment of Descending Thoracic Aortic Aneurysms, Acute Complicated Type B Thoracic Aortic Dissection, and Blunt Aortic Trauma.

About Terumo Aortic

Terumo has combined Bolton Medical and Vascutek to power a dedicated approach focused on aortic innovation. With locations in Glasgow, Scotland and Sunrise, Florida, the integrated company offers advanced technologies such as surgical grafts, hybrid grafts and catheter-based stent graft systems to meet the unique needs of each patient and transform the treatment of aortic disease.

Notes

  • Vascutek and Bolton Medical are both subsidiaries of the Terumo Corporation of Japan, a global medical device company which was founded in 1921 and currently has over 22,000 employees worldwide.
  • Terumo acquired Vascutek in 2002 and Bolton Medical in 2017.
  • Vascutek has 800 employees and Bolton Medical 300.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.